Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

Coppola, Giangennaro; Mangano, Salvatore; Tortorella, Gaetano; Pelliccia, A.; Fels, A; Romano, Angela; Nardello, Rosaria; Habetswallner, Francesco; Licciardi, Felicia; Operto, Francesca Felicia; Pascotto, Antonio

doi:10.1016/j.eplepsyres.2004.03.006

Cited by 46 publications

(47 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early in 2000, LEV had been demonstrated to be effective and well tolerated in refractory partial seizures [11,12,13,14]. So far, it has been proved to be an effective and well-tolerated AED after short-term or long-term administration to patients with partial seizures or various generalized seizures, either in children or adults [15,16,17,18,19,20,21,22,23,24,25,26,27]. …”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures

Xiao

Wang

et al. 2009

Eur Neurol

View full text Add to dashboard Cite

Aim: To evaluate the efficacy and safety of 3,000 mg daily levetiracetam (LEV; Keppra) as an adjunctive therapy for Chinese patients with refractory partial seizures. Methods: This randomized, placebo-controlled trial consisted of an 8-week baseline period followed by a 4-week titration interval and a 12-week maintenance period, and concluded with a 4-week medication withdrawal period or entered an open-label study. LEV was compared with placebo. Results: The 50% responder rate (the proportion of patients with a minimum of 50% reduction in partial seizure frequency) occurred in 46.4% of the LEV group, compared with 39.3% of the placebo group (p = 0.590). The median of the absolute weekly frequency reduction from baseline of partial seizures was 0.66 per week for LEV versus 0.48 per week for placebo (p = 0.187). The most common treatment-emergent adverse events, mostly mild to moderate in severity, were somnolence, dizziness and agitation. Conclusion: In this study, adjunctive therapy with LEV 3,000 mg daily was well tolerated but not as effective as expected in controlling partial seizures in this study population. Considering the lower mean weight of this study population, we suggest the dosage of LEV 3,000 mg daily may contribute to the results.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures

Xiao

Wang

et al. 2009

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…Moreover, levetiracetam seems to be well tolerated, with relatively little adverse effects (Hovinga, 2001;Coppola et al, 2004). To establish the extent to which excessive drug-induced developmental apoptosis is a risk factor predictive of adverse behavioral outcomes in the clinical setting, additional preclinical and clinical studies are warranted.…”

mentioning

confidence: 99%

Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus Polytherapy

Kim

Kondratyev²,

Gale³

2007

J Pharmacol Exp Ther

124

126

View full text Add to dashboard Cite

The aim of this study was to test the potential neurotoxicity of three antiepileptic drugs (AEDs), carbamazepine (5H-dibenzepine-5-carboxamide), topiramate [2,3:4,5-bis-O-(1-methylethylidene)-␤-D-fructopyranose sulfamate], and levetiracetam [2-(2-oxopyrrolidin-1-yl)butanamide], in the developing rat brain, when given alone or in combinations. The extent of cell death induced by AEDs was measured in several brain regions of rat pups (postnatal day 8) by terminal deoxynucleotidyl transferase dUTP nick-end labeling assay 24 h after drug treatment. Carbamazepine alone did not increase neurodegeneration when given in doses up to 50 mg/kg, but it induced significant cell death at 100 mg/kg. When combined with phenytoin, carbamazepine, 50 but not 25 mg/kg, significantly exacerbated phenytoin-induced cell death. Although topiramate (20 -80 mg/ kg) alone caused no neurodegeneration, all doses exacerbated phenytoin-induced neurodegeneration. Levetiracetam (250 -1000 mg/kg) alone did not induce cell death, nor did it exacerbate phenytoin-induced neurodegeneration. Of the combinations examined, only that of levetiracetam (250 mg/kg) with carbamazepine (50 mg/kg) did not induce neurodegeneration. Our data underscore the importance of evaluating the safety of combinations of AEDs given during development and not merely extrapolating from the effects of exposure to single drugs. Although carbamazepine and topiramate alone did not induce neuronal death, both drugs exacerbated phenytoin-induced cell death. In contrast, because cotreatment with levetiracetam and carbamazepine did not enhance cell death in the developing brain, it may be possible to avoid proapoptotic effects, even in polytherapy, by choosing appropriate drugs. The latter drugs, as monotherapy or in combination, may be promising candidates for the treatment of women during pregnancy and for preterm and neonatal infants.

show abstract

“…Coppola et al (2004) включили в исследование 99 детей, подростков и молодых взрослых (в возрасте от 12 месяцев до 32 лет, средний возраст -14 лет) с резистент-ной к терапии симптоматической или криптогенной парциальной или генерализованной эпилепсией. Леве-тирацетам применяли в дополнительной терапии.…”

Section: детской неврологииunclassified

“…Таким образом, в целом урежение при-ступов на 50 % и более достигнуто у 22 % пациентов. Легкие и транзиторные побочные эффекты (преимуще-ственно раздражительность и сонливость) зарегистри-рованы у 17 (17,2 %) пациентов [26].…”

Section: детской неврологииunclassified

“…Из 175 пациентов, прошедших период скрининга, 116 были рандомизированы (60 получали леветирацетам и 56 плацебо) и включены в популяцию для ITT-анализа (intention-to-treat analysis -анализ в зависимости от назначенного лечения); 111 пациен-тов завершили исследование. Доля респондеров (детей с уменьшением средней ежедневной частоты фокаль-ных приступов) при проведении 48-часового видео-ЭЭГ-мониторинга (первичный параметр эффективно-сти) составила 43,1 % для леветирацетама и 19,6 % для плацебо (p = 0,013); отношение шансов (ответ на лечение) -3,11 (95 % доверительный интервал (ДИ) 1,26). Средний процент редукции ежедневной частоты фокальных приступов по сравнению с исход-ным уровнем составил 43,6 % для леветирацетама и 7,1 % для плацебо; различия между лечебными груп-пами -39,2 % (95 % ДИ 17,5-62,2; p < 0,001).…”

Section: детской неврологииunclassified

See 1 more Smart Citation

Efficacy and Tolerability of Levetiracetam (Keppra®) in the Treatment of Epilepsy: Review of Literature

Мухин¹,

Пылаева²

2015

Rus. ž. det. nevrol.

View full text Add to dashboard Cite

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

Cited by 46 publications

References 9 publications

Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures

Efficacy and Safety of Levetiracetam (3,000 mg/Day) as an Adjunctive Therapy in Chinese Patients with Refractory Partial Seizures

Antiepileptic Drug-Induced Neuronal Cell Death in the Immature Brain: Effects of Carbamazepine, Topiramate, and Levetiracetam as Monotherapy versus Polytherapy

Efficacy and Tolerability of Levetiracetam (Keppra®) in the Treatment of Epilepsy: Review of Literature

Contact Info

Product

Resources

About